CZChunyan Zhang

Chunyan Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chunyan Zhang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CK20/CK7 double-negative merkel cell carcinoma arising within a previously photodynamic-therapy-treated actinic keratosis field: a case report

    by Min Liu, Xitao Wang, Xiaofang Ping, Chunyan Zhang

    Background: Photodynamic therapy (PDT) is a first-line treatment for actinic keratosis (AK), particularly in elderly patients. Merkel cell carcinoma (MCC) is a highly aggressive primary cutaneous neuroendocrine malignancy associated with UV exposure and immunosuppression. In skin with severe UV-induced field cancerization, it remains unclear whether PDT might activate occult highly aggressive tumors. Herein, we report an 89-year-old female who developed a CK20/CK7 double-negative MCC at the original AK site within a short period after successful PDT for AK and basal cell carcinoma (BCC), aiming to explore whether the association between PDT and subsequent MCC represents mere coincidence or a potential risk. Case presentation: An 89-year-old female presented with a one-year history of an ulcer on the left nasal ala and an eight-month history of an erythematous patch on the left temporal region. Biopsy confirmed BCC on the left nasal ala and AK on the left temporal region, both treated with PDT (20% ALA under occlusion for 3 hours, 630 nm red light, 80–100 J/cm², three sessions). At the 3-month follow-up, both lesions had healed well. Eight months later, a firm, pale-red nodule developed at the original AK site. Histology revealed small round blue cells in the dermis; immunohistochemistry showed dot-like AE1/AE3 positivity, CD56 and NSE positivity, a Ki-67 index of approximately 75%, and negativity for CK20/CK7 and other markers. The diagnosis was primary cutaneous MCC (T2N0M0, Stage IIA) with positive surgical margins. Given advanced age and anatomical constraints, pembrolizumab was administered for 24 cycles without immune-related adverse events. Post-treatment biopsy showed no viable tumor cells. At the last follow-up in July 2026, the patient remained recurrence-free with a disease-free interval of approximately 12 months. Conclusions: This report describes a case of CK20/CK7 double-negative primary cutaneous MCC. The temporal and spatial proximity between MCC and PDT suggests a possible causal association; however, pre-existing subclinical MCC before PDT or a coincidental second primary tumor in the context of field cancerization cannot be excluded. This report does not undermine the established role of PDT in AK management, but it emphasizes the need for individualized risk assessment and long-term surveillance in elderly patients with extensive field cancerization.

  • Open Access

    Ginsenoside Rg3 promotes chemosensitivity in lung adenocarcinoma organoids via apoptotic pathways

    by Min Liu, Yanxia Li, Bing Han, Ni Zeng, Xiuhua Wei, Xiaoli Xing, Zhongmin Jiang, Xiaozhi Liu, Chunyan Zhang

    Introduction: Platinum-based chemotherapy remains a cornerstone for advanced non-small cell lung cancer (NSCLC), but its efficacy is often compromised by chemoresistance, necessitating strategies to restore drug sensitivity. Ginsenoside Rg3, an active component of Panax ginseng, exhibits anti-tumor and potential chemosensitizing properties, though its mechanisms in clinically relevant models are not fully understood. Methods: We successfully established and characterized three lung adenocarcinoma patient-derived organoid (PDO) lines that faithfully recapitulated the histopathological and molecular features of the parental tumors. The chemosensitizing effect of Rg3 on cisplatin was evaluated by assessing organoid viability, half-maximal inhibitory concentration (IC50), intracellular reactive oxygen species (ROS) levels, and apoptosis via TUNEL assay. Results: Pharmacodynamic evaluation revealed that the combination of Rg3 and cisplatin exerted superior inhibitory effects on organoid viability compared to either agent alone, with a pronounced reduction in IC50. Furthermore, the combination treatment significantly increased intracellular ROS levels and induced apoptosis, as evidenced by TUNEL assay. Discussion: This study provides preclinical evidence for Rg3 as a promising chemosensitizer in lung adenocarcinoma and highlights the value of PDOs as a robust platform for personalized drug response profiling. These findings support further exploration of Rg3 as an adjunct to platinum-based chemotherapy in overcoming chemoresistance.


  • Open Access

    Tu-Si-Zi-Wan reduces D-galactose-induced hepatic and cerebral oxidative damage in aging mice via the Nrf2/ARE pathway

    by Guoping He, Di Wu, Juanjuan Wang, Lei Zhang, Chunyan Zhang, Xiaozhi Liu, Xiangli Han

    The global aging population necessitates safe, multi-target strategies to combat age-related functional decline. Tu-Si-Zi-Wan (TSZW), a classical medicinal-dietary formula documented in ancient Chinese medical texts and composed of Cuscuta chinensis and Dioscorea opposita, demonstrates multitargeted potential, yet its systemic antiaging mechanisms remain unclear. This study investigated the protective effects of TSZW on hepatic and neurological aging through the Nrf2/ARE pathway while exploring its systemic impact on metabolic and immune homeostasis. Firstly, network pharmacology predicted the targets and pathways of TSZW, identifying 113 shared TSZW-aging targets, with Nrf2, IL-6, and HIF-1α as core nodes enriched in oxidative stress-related pathways. Secondly, a D-galactose-induced aging mouse model was established, followed by 4 months of TSZW intervention (low, medium, and high doses). Behavioral tests (open field, novel object recognition, and grip strength), metabolic and inflammatory marker detection, histopathology, and molecular analyses (western blot, quantitative PCR, and immunofluorescence) were used to assess systemic aging phenotypes, oxidative damage, and Nrf2/ARE pathway activity. TSZW dose-dependently improved motor activity, cognition, and muscle strength; restored liver/kidney function (ALT, AST, Cr, and urea); reduced the serum levels of tumor necrosis factor-α, interleukin 6, and interleukin-1β; and attenuated hepatic/neuronal damage. It suppressed the expression of senescence markers (p16, p21, and p53) while increasing the expression of antioxidant enzymes (SOD and GSH-Px) and reducing oxidative damage (MDA and ROS). Mechanistically, TSZW promoted Nrf2 nuclear translocation; upregulated Hmox1, Nqo1, and Gclm expression; and inhibited Keap1. Notably, high-dose TSZW outperformed vitamin E in reversing immune organ atrophy (thymus and spleen indices) and preserving hippocampal neurons. Collectively, TSZW alleviates hepatic and neurological aging via Nrf2/ARE-mediated antioxidant signaling, with concurrent mitigation of systemic aging phenotypes, including immune organ atrophy and chronic inflammation. Its multicomponent synergy highlights Traditional Chinese medicinal cuisine's potential for systemic anti-aging intervention by targeting oxidative stress-inflammation-metabolic signaling crosstalk.

  • Open Access

    Xifeng Jiannao pill mitigates MPTP-induced neuronal apoptosis by reducing inflammation and oxidative stress via MAPK signaling

    by Xiangli Han, Guoping He, Juanjuan Wang, Hanxi Lou, Lei Chen, Lei Zhang, Boyang Liu, Di Wu, Xiaozhi Liu, Su Wang, et al.

    Xifeng Jiannao Pill (XFJNP), a traditional Chinese medicine formulation, has been shown to alleviate clinical symptoms in patients with Parkinson’s disease (PD). However, the underlying mechanisms remain unclear. Therefore, this study employs network pharmacology and molecular biology to investigate the potential therapeutic mechanisms of XFJNP. Firstly, network pharmacology is utilized to screen the major active ingredients and potential targets of XFJNP in the treatment of PD. Following this, pathway enrichment analysis is conducted to gain insights into the underlying mechanisms. Secondly, an MPP+-induced SH-SY5Y cell model and an MPTP-induced PD mouse model to investigate the therapeutic effects and potential mechanisms of XFJNP on PD. By assessing apoptosis, oxidative stress (OS), inflammation, activation of the MAPK pathway, and conducting behavioral tests in mice, we aimed to elucidate the efficacy and underlying mechanisms of XFJNP in treating PD. Network pharmacology analysis indicates that the MAPK signaling pathway holds a key position in mediating the therapeutic effects of XFJNP for PD. In basic experimental studies, XFJNP significantly enhanced the survival rate of MPP+-induced SH-SY5Y cells in vitro, reduced OS and inflammation levels, and increased the expression of tyrosine hydroxylase (TH) protein. In the MPTP-induced PD mouse model, XFJNP effectively improved motor function and reduced the loss of dopaminergic (DA) neurons. Mechanistic studies suggest that XFJNP may mitigate OS and inflammatory responses in the substantia nigra by inhibiting the excessive activation of ERK, JNK, and p38 in the MAPK signaling pathway. Based on the results of network pharmacology analysis and experimental validation, XFJNP displays profound neuroprotective efficacy by modulating the MAPK signaling cascade, markedly diminishing neuroinflammation and mitigating OS-triggered apoptosis of DA neurons in PD models. Graphical Abstract


  • Open Access

    Pan-cancer analyses reveal molecular and clinical characteristics of TET family members and suggests that TET3 maybe a potential therapeutic target

    by Chunyan Zhang, Jie Zheng, Jin Liu, Guoqiang Xing, Shupeng Zhang, Hekai Chen, Jian Wang, Zhijiang Shao, Yongyuan Li, Zhongmin Jiang, et al.

    The ten eleven translation (TET) family genes involve a wide range of biological functions in human cancers. However, few studies have comprehensively analyzed the correlation between TET family members and the molecular phenotypes and clinical characteristics of different cancers. Based on updated public databases and integrated several bioinformatics analysis methods, we evaluated expression level, somatic variation, methylation level, prognostic values of TET family gene and explore the association between expression of TET family genes and pathway activity, TME, stemness score, immune subtype, clinical staging, drug sensitivity in pan-cancer. Molecular biology and cytology experiments were used to validate the potential role of TET3 in tumor progression. Each TET family gene exhibits differentiated expression in at least ten detected tumors. The frequency of single nucleotide variation (SNV) of TETs gene was 91.24%, with most missense mutation type, and the main types of copy number variation (CNV) are heterozygous amplification and deletion. The TET1 gene is highly methylated, while the TET2 and TET3 genes are hypomethylated in most cancers, and that closely related to patient prognosis. Pathway activity analysis shows that the TET family genes are involved in multiple signaling pathways such as cell cycle, apoptosis, DNA damage response, hormone AR, PI3K/AKT, and RTK. In addition, the expression level of TET family genes also affects the clinical stage of tumor patients, increases or inhibits the sensitivity of chemotherapy drugs, and then affects the prognosis of patients by participating in the regulation of tumor microenvironment (TME), cellular stemness potential, and the immune subtype. It is particularly pointed out that TET3 plays a role in promoting cancer progression in various tumors, and silencing TET3 can inhibit tumor malignancy and increase chemotherapy sensitivity. These findings may elucidate the role of TET family genes in cancer progression and provide insights for further research on TET3 as a potential target for pan-cancer.

  • Open Access

    Saikosaponin D improves chemosensitivity of glioblastoma by reducing the its stemness maintenance

    by Jin Liang, Jing Sun, Aibin Liu, Lei Chen, Xiaofang Ma, Xiaozhi Liu, Chunyan Zhang